Skip to content

Feasibility Clinical trial of endovascular EEG Measurement Device

Feasibility Clinical trial of endovascular Electroencephalogram Measurement Device - eEEG feasibility trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032220543
Enrollment
5
Registered
2022-12-26
Start date
2023-02-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intractable epilepsy

Interventions

As the WADA test is performed, the test device is temporarily implanted in the cerebral vein from the jugular vein. The eEEG measurements will be performed at the time of the test device implantation

Sponsors

Matsumaru Yuji
Lead Sponsor
E.P.Medical Inc.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Intractable epilepsy patients 2) Patients for whom the WADA test is performed 3) Patients with the vascular anatomy that allows catheter placement into either the cavernous sinus, transverse sinus, or superior sagittal sinus 4) Patients between the ages of 18 and 70 (at the time of obtaining consent)

Exclusion criteria

Exclusion criteria: 1) Patients with intellectual disability of moderate level or higher (*1) 2) Patients with occlusion or thrombus in the common carotid artery or internal jugular vein 3) Patients who are receiving antithrombotic therapy 4) Patients with a predisposition to bleeding or coagulation abnormalities (*2) 5) Patients allergic to contrast media 6) Patients with metal allergies 7) Patients who are pregnant or of childbearing potential 8) Patients who are judged by the investigator to be inappropriate to participate in this study. *1: The criteria for intellectual disability are as follows Mild: able to work Moderate: Able to answer questions but unable to work Severe: Unable to speak *2: Criteria for predisposition to bleeding and coagulation abnormalities are as follows Platelet count: less than 100,000/micro L APTT: 39 seconds or longer PT-INR: 1.1 or higher

Design outcomes

Primary

MeasureTime frame
eEEG acquisition performance / Confirmation of similarity with EEG acquired from scalp electrode

Secondary

MeasureTime frame
/ Induction of electroencephalogram (eEEG) changes by propofol / Whether or not the opening and closing of the eyes induce eEEG changes. / Comparison of signal sensitivity (voltage) with scalp electrode EEG / Confirmation of lateralization match (when a focus can be diagnosed by the test equipment during the WADA test, comparison with the results of focal identification by subdural electrodes to be performed later ). / Confirmation of tip electrode position during WADA test. / Success rate of the procedure (i.e., was the device able to reach the target vessel while the microcatheter was in the intended area?) /Safety endpoints / Rate of bleeding and thrombosis / Rate of intracorporeal remnants / Total adverse events / Total device failures *Adverse events will be collected from the time when the study device is inserted until the telephone interview one week later.

Contacts

Public ContactYuji Matsumaru

University of Tsukuba Hospital

yujimatsumaru@md.tsukuba.ac.jp+81-29-853-3199

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026